Aim — to evaluate the effectiveness of the Remaxol in the correction of hemostatic system in patients with severe acute peritonitis. Material and methods. 52 patients with acute peritonitis of different severity were examined, and divided into 4 groups: I — mild, II — moderate, III — severe. The patients of these groups had treated using standard therapy. The IV group had patients with severe peritonitis, who received an additional Remaxol. The hemostasis system was evaluated using a TEG 5000 thromboelastograph and biochemical tests. Results. It has been established that the acute peritonitis is accompanied by significant hemostatic disorders — hypercogulation and hyperfibrinolysis, independently of the disease severity. Conclusion. In the severe peritonitis, disorders of the coagulation-lytic system were especially expressed. The use of the Remaxol in patients of this group led to a decrease the blood coagulation disorders.